ArticleJournal of perinatology : official journal of the California Perinatal Association2025
Can N-terminal pro-brain natriuretic peptide accurately diagnose chronic pulmonary hypertension among extremely low gestational age neonates: A Retrospective Cohort Study.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Echocardiographic Detection of Pulmonary Hypertension and Right Ventricular Failure in Infants with Bronchopulmonary Dysplasia: A Survey of the BPD Collaborative.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the utility of N-terminal pro-brain natriuretic peptide (NT pro-BNP) for screening and diagnosis of chronic pulmonary hypertension (cPH) in extremely low gestational age neonates (ELGANs < 28 weeks gestational age [GA]).
methodsWe conducted a retrospective cohort study analyzing paired echocardiogram results and serum NT pro-BNP concentrations (ng/L) in ELGANs. The accuracy of NT pro-BNP for diagnosing cPH and determining the optimal cut-off for cPH screening and diagnosis was evaluated using receiver operating characteristics (ROC) curves and Youden's index, respectively.
resultsAmong the 35 included ELGANs, the area under the ROC curve for diagnosing cPH using NT pro-BNP levels combined with GA < 25 weeks and BPD was 0.70 (95% CI: 0.51-0.89). An NT pro-BNP value of 1129 showed a sensitivity of 85%, while a value of 2674 demonstrated a specificity of 95%, indicating its potential role in screening and diagnosing cPH.
conclusionsNT pro-BNP is a promising biomarker for screening and diagnosing cPH in ELGANs.
Identifiers
41233504What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.